Revolution Medicines, Inc. RVMD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.13B+65.4% | $987.33M+66.6% | $880.49M+59.2% | $769.73M+51.2% | $680.53M+44.1% | ||
| $261.28M+140% | $195.04M+102% | $156.57M+55.4% | $127.77M+38.4% | $108.9M+27.8% | ||
| $1.39B+75.7% | $1.18B+71.5% | $1.04B+58.6% | $897.5M+49.2% | $789.43M+41.6% | ||
| -$1.39B-75.7% | -$1.18B-71.5% | -$1.04B-58.8% | -$897.5M-49.4% | -$789.43M-42.8% | ||
| $36.43M— | $24.23M— | $12.3M— | $867K— | —— | ||
| $18.4M-79.8% | $54.33M-38.7% | $75.32M-12.9% | $84.68M+8.6% | $91.17M+40.1% | ||
| -$1.37B-96.4% | -$1.13B-88.3% | -$961.73M-69.7% | -$812.81M-55.5% | -$698.26M-43.1% | ||
| -$1.37B-96.7% | -$1.13B-88.5% | -$960.98M-69.5% | -$812.06M-56.4% | -$697.51M-44.0% | ||
| -$7.10-77.1% | -$5.94-65.9% | -$5.18-41.5% | -$4.51-21.6% | -$4.01-5.0% | ||
| -$1.38B-76.1% | -$1.17B-72.0% | -$1.03B-59.1% | -$890.67M-49.7% | -$782.71M-42.9% | ||
| -$1.39B-75.7% | -$1.18B-71.5% | -$1.04B-58.8% | -$897.5M-49.4% | -$789.43M-42.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Revolution Medicines, Inc. profitable?
- Revolution Medicines, Inc. is not currently profitable: it reported a net loss of $1.4B over the trailing twelve months, a -76423.3% net margin.
- What is Revolution Medicines, Inc.'s earnings per share?
- Revolution Medicines, Inc.'s diluted EPS over the trailing twelve months is $-7.10.
- Where does Revolution Medicines, Inc.'s income statement data come from?
- Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.